Scott Greer has been appointed chairman of the board of directors of Ablexis, an antibody technology company.
Greer founded and served as CEO and later as chairman of the board of Abgenix, until its acquisition by Amgen in 2006. He also served as chairman of the board of Sirna Therapeutics before its $1.1 billion acquisition by Merck in 2007. In the past, Greer has served on several other boards, including Affymax and Illumina. He is currently the managing director of Numenor Ventures.
Sequenom has elected several members to its board of directors who will serve until 2011, including: Ernst-Günter Afting; Kenneth Buechler; John Fazio; Harry Hixson; Richard Lerner; Ronald Lindsay; and David Pendarvis.